Alleged 99.9% efficacy: US approves Gilead's twice-yearly injection to prevent HIV

The US Food and Drug Administration on Wednesday approved Gilead's twice-yearly HIV prevention shot, Yeztugo, a breakthrough hailed for its 99.9% efficacy – but priced at over $28,000 a year, raising concerns over global accessibility.